Autologous stem cell therapy (ACT) has been proposed to prevent irradiated victims from bone marrow (BM) aplasia by grafting hematopoietic stem and progenitor cells (HSPCs) collected early after damage, provided that a functional graft of sufficient size could be produced ex vivo. To address this issue, we set up a baboon model of cell therapy in which autologous peripheral blood HSPCs collected before lethal total body irradiation were irradiated in vitro (2.5 Gy, D 0 1 Gy) to mimic the cell damage, cultured in small numbers for a week in a serumfree medium in the presence of antiapoptotic cytokines and mesenchymal stem cells (MSCs) and then cografted. Our study shows that baboons cografted with expanded cells issued from 0.75 and 1 Â 10 6
Autologous stem cell therapy (ACT) has been proposed to prevent irradiated victims from bone marrow (BM) aplasia by grafting hematopoietic stem and progenitor cells (HSPCs) collected early after damage, provided that a functional graft of sufficient size could be produced ex vivo. To address this issue, we set up a baboon model of cell therapy in which autologous peripheral blood HSPCs collected before lethal total body irradiation were irradiated in vitro (2.5 Gy, D 0 1 Gy) to mimic the cell damage, cultured in small numbers for a week in a serumfree medium in the presence of antiapoptotic cytokines and mesenchymal stem cells (MSCs) and then cografted. Since the Chernobyl accident, cytokine administration and allogeneic grafting have remained the gold standards for the treatment of radiation-induced (RI) myelosuppression, in cases of intermediate medullary damage and eradication respectively. 1 In accidental contexts, the rationale of cytokine treatment is the heterogeneity of cell damage due to the geometry of exposure and the dose attenuation related to the body's thickness. Moreover, the persistence of ubiquitous radio-resistant HSPCs is also suspected. However, the relative efficacy of cytokines, especially regarding granulocytic recovery, is known to dramatically decrease with dose escalation. This points out the necessity of a cell support in such cases. In an attempt to provide it without embarking on the well-known complications of allografting (mainly graft versus host disease), autologous cell therapy (ACT) has been proposed as a new strategy, especially in the mass casualties context of a nuclear/ radiological attack. [2] [3] [4] [5] This treatment would consist of the reinfusion of ex vivo expanded cells produced by residual hematopoietic stem and progenitor cells (HSPCs) collected soon after irradiation. In fact, as we previously demonstrated, one of the most important concerns about ACT is collecting sufficient amounts of underexposed or radioresistant HSPCs shortly after total body irradiation (TBI), either from peripheral blood (PB) or from bone marrow (BM), to produce efficient grafts. 2 This problem is mainly due to the 'apoptotic burst' that occurs during the first hours following TBI. 6 Culturing HSPCs could allow significant amplification of the HSPC pool but the efficacy of cytokines may be reduced in cases of damaged cells. Moreover, the hematopoietic potential of rescued cells is suspected to be impaired. 7 In fact, the feasibility of this treatment is still debatable. To date an elegant study has demonstrated the capacity of BM HSPCs collected from irradiated animals to engraft lethally irradiated mice, provided the cells be expanded and grafted in large amounts. However, these results have to be confirmed in the nonhuman primate model that is definitely more relevant to humans in terms of stem cell biology (polyclonal hematopoiesis, low evidence of stem cell plasticity). 8 Regarding the monkey model, a recent study suggests the hematopoietic potential of cultured BM mononuclear cells issued from underexposed areas in shielded exposure. 9 However, the hematopoietic potential of these grafts appeared variable (one animal of five engrafted in a 4.4/10 Gy schedule) and one can argue that in practice, the identification of such areas would not be easy. BM MNCs could also be a source of mesenchymal progenitors, 10 which could be useful to regenerate nonhematopoietic tissues. Moreover, marrow cells are known to exhibit a delayed hematopoietic potential in comparison with PB cells which represent an alternative source of cells, provided that efficient short-term mobilizing agents were available. 2 To address these issues, we set up a baboon model of cell therapy in which autologous PB HSPCs collected before lethal TBI were irradiated in vitro to mimic the cell damage, cultured for a week in a serumfree medium in the presence of antiapoptotic cytokines (Stem Cell Factor þ FLT-3 ligand þ Thrombopoietin þ Interleukin-3 ¼ 4F) and then grafted. We have previously shown that the homogeneous dose of 2.5 Gy induces the death of 95% of HSPCs and mimics the damage undergone by underexposed BM areas after heterogeneous TBI in the range of 8-10 Gy. 6 This model allowed us to explore major aspects of ACT, circumventing the difficulty of the collection phase.
As stromal and endothelial cells have been proposed for some years to sustain HSPCs during culture and are suspected to enhance hematopoietic recovery after cografting in preclinical or clinical models, [11] [12] [13] [14] [15] [16] [17] we evaluated the potential usefulness of MSCs in the ACT context. We have previously shown the capacity of MSCs to cooperate with 4F to reduce apoptosis of CD34 þ cells exposed to doses up to 4 Gy in vitro and to preserve their hematopoietic potential in vitro. 18 This in vivo study was aimed at evaluating the hematopoietic potential of the culture. Our results suggest the benefit of using MSCs to improve the hematopoietic potential of low size grafts issued from irradiated HSPCs. In fact coculturing and cografting small amounts of irradiated PB HSPCs increase platelet recovery when compared with historic animals grafted with unmanipulated, unirradiated CD34 þ cells alone. Long-term multilineage engraftment was achieved and MSC engraftment was demonstrated albeit at a low level. However, the reduction of the cell threshold required for recovery is not achieved. Moreover, nonhematopoietic toxicity remains critical in this cohort leading to the death of two cotransplanted baboons in six. Taken together, this nonhuman primate study supports the hypothesis that ACT feasibility appears to be more limited than expected from mouse studies.
Materials and methods

Animals
Adult male baboons (papio anubis) weighing 2573 kg were housed at the CRSSA-accredited animal facility in holding rooms equipped with a reverse-filtered air barrier (n ¼ 9) in individual cages in accordance with the European guidelines on animal care. The present protocol was approved by the French Army Ethical Committee.
CD34
þ cells
At least 2 months before transplantation, PB cells were mobilized using cyclophosphamide for two consecutive days (Endoxan, a gift from Asta Medica, Nanterre, France; 100 mg/kg) and recombinant human granulocyte colonystimulating factor (rhG-CSF, a gift from Amgen-Roche, Neuilly, France; 40 mg/kg/day for 7 days). PB hematopoietic cells were collected by a 2-h leukapheresis on a Spectra cell separator (Cobe, France). Collected cells were incubated with biotinylated class I 12.8 anti-CD34 monoclonal antibody (mAb), then with streptavidin microbeads and separated on immunomagnetic columns (Miltenyi, Bergisch Gladbach, Germany). Mean CD34 þ cell purity (490%) was evaluated using anti-human CD34 mAb clone 566 (Becton Biosciences, San Jose, CA, USA). Cells were cryopreserved in liquid nitrogen until use. In baboon PH951, the capacity of irradiated BM CD34 þ cells to expand on MSCs was evaluated. BM mononuclear (MNCs) cells were collected from humerus and iliac crest and CD34 þ cells purified as described for PB cells.
Mesenchymal stem cells
To allow in vivo cell tracking, human MSCs (huMSCs) were used. HuMSC layers were pre-established by culturing BM cells from an healthy donor (with informed consent) in minimal essential medium MEM-a (Life Technologies, Cergy Pontoise, France) with 10% fetal calf serum (Hyclone Laboratories, Logan, UT, USA) at 371C in air with 5% CO 2 . Adherent cells were passaged at least three times. MSCs were defined as cells positive for CD90, CD105, CD73 and negative for CD45 using mAbs (Becton Biosciences) and FACS analysis. Moreover, the multilineage potential of these MSCs has been shown, in particular towards osteogenic, chondrogenic and adipogenic differentiation. 19 Then cells were cryopreserved in liquid nitrogen until use.
After grafting, human genomic DNA (gDNA) was detected at the BM MNC level in injected bones. We performed nested real time RT-PCR targetting the human beta actin gene spaning intron 3 to exon 3 (BACT: GenBank E00829). Primers used in this study were synthesized by Eurogentec (Saraing, Belgium) and designed with MacVector Software (Accelrys). The 5 0 -3 0 forward (F) and reverse (R) primers selected are as follows: outer primers -F: AGCACACTTAGCCGTGTTCTTTG, R: AGCTTCTCGTTAATGTCACGCAC generating a 377 bp human and baboon DNA fragment (E00829 -1991-2377); inner primers -F: AGTGTGACATGGTGCATCTCTGC, R: ATAGCACAGCCTGGATAGCAACG generating a specific 88 bp human DNA fragment (E00829 -2064-2151) and no baboon DNA fragment. gDNA was isolated from frozen BM (E5.10 5 cells) using a QIAamp s DNA Blood Midi Kit (QIAGEN) according to the manufacturer's instructions. Real-time PCR reactions were carried out with the LC Fast Start DNA Master SYBR Green kit (Roche Diagnostics, using 4 mM/l MgCl 2 and 0.4 mM/l for each primer (final concentration) and using as template 20 ng gDNA for outer PCR and 5 ml of a 1000-fold dilution of outer PCR product for inner PCR. Quantitative PCR was performed using Lightcycler (Roche Diagnostics) for 18 (outer PCR) or 45 (inner PCR) cycles at 951C for 20 s, 551C for 4 s and 721C for 10 s. Assays were carried out in duplicate and amplification specificity was controlled in each sample by fusion characteristics of the PCR product. Quantification was achieved using Cycle threshold (C T ) measured with the second derivative maximum method (LightCycler software v3.5, Roche Diagnostics). Using a mixed human-baboon gDNA standard, this reliable procedure allows accurate quantification up to 0.5% human gDNA (Figure 1a) . At lower concentrations, this method ensures only detection because of the Monte Carlo effect. 20 The Monte Carlo effect is an inherent limitation of PCR amplification from small amounts of any template due to small and random differences in amplification efficiency between individual DNA templates. Baboon samples were analyzed up to 12 months after grafting.
CD34
þ cell culture
Confluent huMSC layers were washed and seeded with CD34 þ cells (1 Â 10 5 cells/ml) irradiated at the dose of 2.5 Gy ( 60 Co g source, dose rate 100 cGy/min). This homogeneous dose induces the cell death of 95% of HSPCs 6 and mimics the damage undergone by underexposed BM areas after heterogeneous TBI in the range of 8-10 Gy. Cultures were then performed for 7 days (75 cm 2 flasks; Corning Costar, Dutscher, Issy-les-Moulineaux, France) using a serum-free medium (CTM-H00 containing human albumin, Mabio-RTM, Tourcoing, France) and a combination of four cytokines, Stem Cell Factor þ FLT-3 ligand þ Thrombopoietin þ Interleukin-3 (4F; 50 ng/ml each). At the end of the culture, an aliquot of nonadherent cells was collected for characterization, as well as an aliquot of adherent cells after trypsinization and all remaining cells were grafted.
Phenotypic analysis of grafts
Ex vivo expanded and unmanipulated cells were characterized using flow cytometry. At the end of the culture, viable nonadherent and adherent cells were counted in a hemocytometer using trypan blue dye exclusion and cytology was performed on May-Gru¨nwald-Giemsastained cytospins. Flow cytometric analysis of cells stained with anti-CD34-PE, -Thy1-FITC (BD Biosciences), -CD2-FITC and -CD41-FITC (Beckman-Coulter) mAbs was made. For myeloperoxidase (MPO) immunodetection, cells were fixed, then permeabilized (Cytofix/Cytoperm kit, Pharmingen BD) and stained with anti-MPO-FITC mAb (Beckman-Coulter). As for adherent cells, results were expressed on total non-MSC cells. MSCs were easily outgated according to morphologic criteria (side and forward scatter).
Transplantation study
The anesthetized baboons placed in a restraining chair were globally exposed to a 60 Co gamma source at a total dose of 2 Â 5.5 Gy (midline tissue dose measured in air; dose rate of 11 cGy/min) on 2 consecutive days (frontal then dorsal irradiation). Dosimetry was performed using ionization chambers and thermoluminescent dosimeters. Animals were grafted 2 days after the second fraction of irradiation. 
Statistical analysis
Results were expressed as means7s.d. Statistical comparisons were made using the nonparametric Mann and Whitney U-test. P-values of less than 0.05 were considered statistically significant.
Results
MSCs allow ex vivo expansion of irradiated HSPCs
Culture of PB CD34
þ cells on MSC in the presence of 4F leads to expansion of total hematopoietic cells ( Â 3.871.8) and CD34 þ cells ( Â 1.570.3), albeit the latter is moderate (Figure 2) . Amplification rates appeared reduced in comparison with culture of unirradiated cells. This is the consequence of the partial protection provided by cytokines and MSCs against RI apoptosis during the first 24 h of culture when occurs most of apoptotic process. In fact, an initial phase of cell depletion was observed (about 20% of surviving CD34 þ cells at that time) followed by an expansion phase. Apoptosis rates of cultured cells remained low after the first day (data not shown). þ cells were given 0.5 (n ¼ 3) and 1 (n ¼ 1) Â 10 6 /kg CD34 þ cells. In fact, there was no significant difference in the amount of PBCD34 þ cells grafted between unirradiated (n ¼ 4) and irradiated (n ¼ 5) groups (P40.05). Moreover, in order to detect any MSC-related therapeutic effect, two of the three baboons grafted with MSCs alone received a higher dose of MSCs (2 Â 10 6 /kg) than that infused into baboons of the cografted group.
Hematopoietic recovery
Short-term PLT recovery was strongly accelerated for two cografted baboons in comparison with baboons grafted with unirradiated cells alone. PLT counts of baboon 626 and baboon 628 rose up to 191 Â 10 9 /l and 208 Â 10 9 /l at day 36 and day 32 post transplantation respectively (Figures 3 and 4) . This shortening of thrombocytopenia did not clearly appear to correlate with the CD34 þ cell dose (put into culture or grafted) as baboon 628 transplanted with the lowest amount of cultured CD34 þ cells exhibited a huge PLT recovery. MSCs sustained in vivo PLT production as D30-D190 PLT AUC of all animals cografted with MSCs and irradiated hematopoietic cells were higher than those of baboons grafted with unirradiated cells alone (Table 3) . However, it can be noted that two of the three baboons of the 0.4 Â 10 6 /kg irradiated CD34 þ cells group died within 22 days without hematopoietic recovery. Baboon 626 exhibited a transient decrease in PLT count between day 80 and day 130 before further complete recovery.
In contrast, ANC recovery was delayed in cografted baboons. Duration of lymphopenia and time to lymphocyte recovery were similar in all assessable animals but baboons 631, 626 and 628 exhibited high lymphocyte levels from day 50 on. Long-term hematopoietic recovery was achieved in surviving baboons of cografted group. Baboon PH951 grafted with cells issued from irradiated BM 
Detection of HuMSCs in BM
Cell tracking was performed in baboons 631, 626 and 628 to evaluate a transitory or stable engraftment of huMSCs. Globally, the expression levels remained below the quantification threshold near 0.5% human gDNA (Figure 1a, b) for all samples. MSCs were only detected up to day 180 in baboons 628 and 626 between 1.2 to 2.7 cycles under the quantification threshold (Figure 1b, c) . Moreover, Baboon 626 exhibited a higher amount of MSCs than baboon 628. Human gDNA was not detected in baboon 631. Thus, the two baboons which exhibited the detectable amounts of MSCs exhibited the shortest thrombocytopenia.
Extrahematologic death
Two of the three baboons grafted with the lowest amounts of hematopoietic cells died before hematopoietic recovery, one from sepsis and the other from gastrointestinal damage. All surviving baboons exhibited a transient period of anorexia and weight loss was accounted for by a huge gastrointestinal toxicity ( Figure 5 ). 
Discussion
Cografting cells resulting from HSPCs cultured in the presence of accessory cells could be a major tool to improve engraftment after reinfusion, through a stem cell pool increase and a synergistic effect provided by stromal cells. As colony-forming units-fibroblast have been demonstrated to be radiosensitive in vivo with only a small radioresistant subpopulation leading to a nonfunctional stem cell niche after TBI, 22, 23 regeneration of stem cell niche could be a pertinent strategy. Based on preliminary studies in our laboratory and results of other teams, 13, 15, 16, 18 we developed a model of CD34 þ cell and MSC coculture and then cografting. MSCs are multipotent cells present in various adult tissues including the BM as well as in fetal tissues such as lung. [24] [25] [26] MSCs have been demonstrated in vitro to support megakaryocyte and proplatelet formation from
CD34
þ cells in a serum-free medium without exogenous cytokines. 27 Moreover, the capacity of human stromal cells to support the expansion of cord blood (CB) progenitors and SCID-mice repopulating cells in the presence of TPO, SCF and FL has been demonstrated. 28 Herein we confirm 18 that 4F and MSCs allow amplification of damaged CD34 þ cells even though the amplification rates are reduced in comparison with unirradiated cells. This capacity appears mainly related to apoptosis reduction during the first 24 h of culture. Then we show, using a nonhuman primate model, the hematopoietic potential (short-term engraftment and longterm hematopoiesis) of damaged CD34 þ cells, rescued ex vivo using a short phase of culture in the presence of antiapoptotic cytokines and MSCs, and then cografted. The latter were injected intramedullarly to avoid the sequestration in capillary beds reported in different tissues, albeit this point is much debated. [29] [30] [31] [32] [33] One must bear in mind that, in our model, no more than 20% of the irradiated CD34 þ cells put into culture remain viable after the first 24 h (that is to say about 0.2-0.1 Â 10 6 /kg CD34 þ cells) and contribute to the graft after expansion. When comparing with animals transplanted with similar amounts of unirradiated, unmanipulated CD34 þ cells, no improvement of granulopoiesis could be observed but thrombopoiesis appeared stimulated in the MSC cografted group. Two baboons cografted with MSCs exhibited a dramatic increase in PLT recovery and PLT AUC were higher for all surviving animals of this group. It is very likely that culture in the presence of MSCs and 4F combination (including TPO) enhanced expansion of megakaryocytic precursors from PB CD34 þ cells that were preserved from irradiation by 4F. Subsequently after infusion, these cells ameliorated PLT recovery in all of these animals. However, the discrepancy between granulopoietic and thrombopoietic recovery has to be explored as ex vivo cell differentiation was balanced between the two lineages. One animal was cografted with cells issued from BM and MSCs to test our hypothesis and showed a delayed PLT recovery in comparison with PB cografted animals. However, no definitive conclusion can be drawn from this unique animal.
The respective usefulness of the coculture and the cografting phases remains to be determined. Interestingly, baboons grafted with cultured hematopoietic cells issued from 0.5 Â 10 6 /kg unirradiated CD34 þ cells 21 exhibited a delayed PLT recovery when compared with baboons 631, 626 and 628. The beneficial effect of MSCs after transplantation could be related to the local production of growth factors or to direct participation. Our study did not allow us to elucidate this question. At the time of transplantation, based on the BM MNC content in one humerus, 34 the ratio of grafted MSCs to autologous BM MNCs approximately equals 1/300 cells. Then, a mid-term residence of human MSCs was observed, although below the threshold of cell quantification (0.5%). However, these detectable levels are likely to reach physiological levels of medullary MSCs, reported as being between 1/10 000 and 1/100 000 BM MNCs. 24 Thus, our study does not suggest xenogeneic MSC amplification in vivo but is more compatible with growth factor production. As to the animals grafted with MSCs alone, they died within 22 days without hematopoietic recovery, which suggests the failure of MSCs as a single treatment. This indicates that a rapid stimulation of radioresistant endogenous stem cells by MSCs is very unlikely to have occurred and did not result in the same strong PLT recovery as that observed in cografted animals. This is consistent with recent data of our team, which show that intramedullary MSC infusion fail to enhance hematopoietic recovery after 4F administration in irradiated macaques. 35 Unfortunately, it has to be noted that in our baboon model, the hematopoietic recovery became variable when reducing the CD34 þ cell input. Only one of the three baboons grafted with cells issued from 0.4 Â 10 6 /kg irradiated PB CD34 þ cells exhibited a quite good recovery and the other two died before 30 days. Overall, our study indicates the current limit of MSC use in the context of very small grafts. Regarding ACT, it shows that using MSCs it would be very unlikely to reach the cell threshold 36 that we previously evaluated as being close to either 0.5 Â 10 6 /kg unmanipulated, unirradiated PB CD34 þ or 0.3 Â 10 6 /kg unirradiated PB CD34 þ cells if cultured for a week in the presence of 4F. 21 The latter correspond, after culture, to 3.870.45 Â 10 6 /kg CD34 þ cells. In fact, using a baboon model, we previously reported that about 1 Â 10 6 CD34 þ cells/100 ml BM or 1 Â 10 6 CD34 þ cells/l leukapheresis could be collected after a 6 Gy TBI. 2 Thus, if extrapolated to human victims, a 10 l blood leukapheresis would allow the collection of a graft of 0.1 Â 10 6 /kg CD34 þ cells on average. 2 Moreover, such a strategy would necessitate HLA typing and allogeneic MSC banking. Regarding the nuclear accident context, our results are less encouraging than previous mouse results using accessory cells. From our point of view, this illustrates the necessity of including large animal models in stem cell biology evaluations. In fact, improving the collection phase remains crucial in a small graft context. New perspectives could allow it in the future, based on promising short-term mobilizing agents under investigation. 37, 38 Using new molecules involved in hematopoietic stem cell self-renewal could also increase the graft size. 39 In fact, as we recently reported, emergency cytokine treatment using 4F offers the opportunity to rescue victims irradiated at high doses. 40, 41 The present study suggests that ACT could rather represent a complementary approach to cytokine treatment than a single therapy. Nevertheless, new autologous cell drugs, mainly involving multipotent stem cells, could represent useful tools to treat RI nonhematopoietic toxicity. 10 
